Get the Stockscreener App
1.68
6.67%
-0.12
Pyxis Oncology Inc stock is traded at $1.68, with a volume of 908.23K.
It is down -6.67% in the last 24 hours and down -49.70% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$1.80
Open:
$1.79
24h Volume:
908.23K
Relative Volume:
0.88
Market Cap:
$140.13M
Revenue:
$13.86M
Net Income/Loss:
$-81.74M
P/E Ratio:
-1.2887
EPS:
-1.3036
Net Cash Flow:
$-66.98M
1W Performance:
-17.24%
1M Performance:
-49.70%
6M Performance:
-1.18%
1Y Performance:
-49.85%
1-Day Range:
$1.66
$1.79
1-Week Range:
$1.66
$2.08
52-Week Range:
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.68 | 140.13M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-26 | Initiated | Wells Fargo | Overweight |
| May-05-26 | Initiated | Wedbush | Outperform |
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Form 4 Pyxis Oncology Inc For: 10 October By Investing.com - Investing.com South Africa
Form 4 Pyxis Oncology Inc For: 10 October By Investing.com - Investing.com Nigeria
Form 4 Pyxis Oncology Inc For: 10 October By Investing.com - Investing.com UK
Warrants for 4.9 million shares are included in a passive stake in Pyxis Oncology (PYXS). - Stock Titan
Warrants bought at Pyxis Oncology (PYXS) cannot be exercised yet, and their count is corrected. - Stock Titan
Pyxis Oncology stock fell 9.82 percent on October 6 after financing - AD HOC NEWS
A passive holder reports over 5% of Pyxis Oncology (PYXS), with some warrants excluded. - stocktitan.net
Form 4 Pyxis Oncology Inc For: 2 October By Investing.com - Investing.com Nigeria
Form 4 Pyxis Oncology Inc For: 2 October By Investing.com - Investing.com Canada
GordonMD Discloses 17.5% Stake in Pyxis Oncology Including Warrants - Kalkine Media
A 10% owner buys $2.90 share-and-warrant packages in Pyxis Oncology (PYXS). - Stock Titan
An ownership cap restricts warrant exercise for a Pyxis Oncology (PYXS) investor. - Stock Titan
Pyxis Oncology Closes $110 Million Public Offering to Advance MICVO Clinical Development - Quiver Quantitative
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering - GlobeNewswire
Pyxis Oncology Raises $102.8 Million Net in Underwritten Equity Offering Led by Leerink, Guggenheim, Wells Fargo - TradingView
Form 424B5 Pyxis Oncology Inc For: 1 October By Investing.com - Investing.com Canada
Latham Advises on Pyxis Oncology’s Up to US$282.6 Million Public Offering - Legal Desire
Pyxis Oncology Prices Public Offering of Common Stock, Warrants - marketscreener.com
Pyxis Oncology prices $110 million public offering - Investing.com
Pyxis Oncology prices $110 million public offering By Investing.com - Investing.com Canada
Pyxis Oncology launches public offering to fund MICVO Phase 3 development - scanx.trade
Pyxis Oncology stock falls on public offering announcement - Yahoo Finance UK
Pyxis Oncology stock falls on public offering announcement - Yahoo Finance
Pyxis Oncology launches public offering of stock and warrants By Investing.com - Investing.com Canada
Pyxis Oncology Announces Proposed Registered Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants - Quiver Quantitative
Pyxis Oncology (Nasdaq:PYXS)Stock Analysis - Simply Wall Street
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS) - Seeking Alpha
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com Nigeria
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright By Investing.com - Investing.com Australia
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know - webull.com
Pyxis Oncology (NASDAQ: PYXS) to Launch Phase 3 Trial for MICVO in Mid-2027 Following Promising Phase 1 Results - Kalkine Media
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Nigeria
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $6 to $19 - Moomoo
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Australia
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Australia
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - investing.com
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Nigeria
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Canada
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com Australia
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Canada
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com UK
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2026-09-10 - Seeking Alpha
Wedbush raises Pyxis Oncology stock price target on trial data - investing.com
Wedbush raises Pyxis Oncology stock price target on trial data - Investing.com
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):